In this article, we are going to take a look at where BridgeBio Pharma, Inc. (NASDAQ:BBIO) stands against the other best mid cap biotech stocks to buy. On March 6, Jared Holz, Mizuho health care ...

H.C. Wainwright analyst Raghuram Selvaraju raised the firm’s price target on BridgeBio (BBIO) to $53 from $49 and keeps a Buy rating on the ...

Andrea Ellis, a director at $BBIO, sold 10,000 shares of the company on 04-14-2025 for an estimated $350,000. We received data on the trade from a recent SEC filing ...

BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In trading on Wednesday, shares of BridgeBio Pharma Inc (Symbol: BBIO) crossed below their 200 day moving average of $28.50, changing hands as low as $28.32 per share. BridgeBio Pharma Inc shares ...

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...